<P>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/centre-recherche-et/biotechnology-cluster-lyon,p,21,EN.jsp" target=_blank>The Lyon Gerland site, one of the Europe’s most important science parks </A></STRONG>dedicated to life sciences and innovative technologies, continues to attract large <A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>biotechnology projects</A>. </STRONG></P> <P align=justify>&nbsp;</P> <P align=justify>This zone, which contains <STRONG>30 public research laboratories and 2000 companies</STRONG>, is at the heart of <STRONG>the <A title="" href="https://www.aderly.com/lyon-biopole-pole-centre-recherche-scientifique/index,p,98,EN.jsp" target=_blank>Lyonbiop&#244;le global competitiveness cluster </A>for the study of infectious diseases</STRONG>. The cluster hosts 5000 private sector employees and 2,750 researchers. <STRONG><STRONG><A title="" href="http://www.lyonbiopole.com/News/New-General-Manager-for-Lyonbiopole–Florence-AGOSTINO-ETCHETTO.html" target=_blank>Florence Agostino-Etchetto was recently appointed as General Manager of Lyonbiop&#244;le</A></STRONG></STRONG>, and intends to achieve the planned strategic goals by 2018. </P> <P align=justify>&nbsp;</P> <P align=justify><A title="" href="https://www.aderly.com/lyon-economic-news/lyon-biopole-pole-centre-recherche-scientifique-news-LYONBIOPOLE-A-HOST-OF-NEW-BIOTECH-PROJECTS-,n,7176,EN.jsp" target=_blank>A first large project in the Gerland area</A> is the <STRONG>extension of the Jean M&#233;rieux bio-safety level 4 laboratory</STRONG>, which should be extended by 200 square meters by the end of 2013 in order to host a biological resource center.&nbsp; <STRONG>Even more ambitious is the <A title="" href="https://www.aderly.com/lyon-economic-news/centre-recherche-et-news-A-NEW-PLANT-FOR-AGUETTANT-IN-LYON-GERLAND,n,6711,EN.jsp" target=_blank>Gerland 2 laboratory initiated by Aguettant</A></STRONG>, which will have a surface area of 10,000 square meters and host the company’s headquarters, a factory, the laboratory, and an R&amp;D center. In total, almost 300 employees should move to these premises by 2015.</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/france-biotechnologies-biotech/company-lyon-genzyme-biotechnology-biotech,p,122,EN.jsp" target=_blank>Genzyme, a subsidiary of Sanofi</A></STRONG>, will host a new state-of-the-art core facility</STRONG> dedicated to manufacturing active immunotherapy products for the company Transg&#232;ne.</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="https://www.aderly.com/france-pharmaceutique/company-lyon-sanofi-aventis-pharmaceutical,p,130,EN.jsp" target=_blank>Sanofi, the biggest employer in metropolitan France </A></STRONG>and world leader in vaccines, and Merial, specializing in veterinary medication and vaccines, will join their activities together on one single site in 20</STRONG>16. Bringing together the 150 researchers from both companies will allow them to "<EM>work together more closely and take advantage of the synergies created</EM>", stated Olivier Charmeil, CEO of Sanofi Pasteur, during a press conference. </P> <P align=justify>&nbsp;</P> <P align=justify><STRONG><STRONG><A title="" href="http://www.bioaster.com/home.html" target=_blank>Bioaster,&nbsp;a Technology Research Institute (ITR) </A></STRONG>focused on&nbsp; infectious diseases and microbiology, will set up on a new 6,500 square-meter site in 2014</STRONG>, composed of ready-to-use research laboratories, which will be used by Accinov and others. <STRONG><STRONG><A title="" href="http://www.accinov.com/" target=_blank>Accinov, the soon-to-be-opened innovation platform </A></STRONG>will provide world-class services integrating ready-to-process facilities to biotechnology start ups and SMEs</STRONG> who aim to develop new therapeutic products and technologies.</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>Furthermore, <STRONG><A title="" href="http://www.bioaster.com/news/bioaster-and-vaiomer-research-partnershiph.html" target=_blank>Bioaster and the French biotechnology company Vaiomer entered into a partnership</A><A href="http://www.bioaster.com/news/bioaster-and-vaiomer-research-partnershiph.html"></STRONG></A><A title="" href="http://www.bioaster.com/news/bioaster-and-vaiomer-research-partnershiph.html" target=_blank> </A></STRONG>on research to develop novel blood bacterial biomarkers. Their main goal is to optimize and validate novel biomarkers which will predict the onset of diabetes and its cardiovascular disease complications. Thus, diagnostic tests based on the project results will provide physicians with powerful tools to evaluate disease risks at early stages and prevent it.<BR></P>